Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/a2e2b408-81c8-4e45-9b4c-807750556b31/

URGN

UroGen Pharma Ltd
Chart
$26.85
Latest Week 2026-06-05
HealthcareBiotechnologySMALL
Snapshot 2026-06-07 · 0.0w · Fresh
0.21
OS Score
36.0%
Value
35.0%
Quality
35.0%
Momentum
1/9
F-Score
0.355
QV
StrategiesValueQualityMomentumCompositeInteractionsFactor AnalysisTrendsFundamentals
Strategy Eligibility
2 of 23 passing
★
OS Composite
✗
↗
Trending Value
✗
◆
Quality × Value
✗
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
✗
◇
VC2 Cheapest
✗
📐
EBITDA/EV
✗
◐
Veiled Value
✗
▣
Piotroski Bargains
✗
🔬
Quality Compounders
✗
📈
Consistent Earners
Noneyr
🌱
GARP
✗
🔄
Shareholder Yield
✗
💰
High Yield
✗
🚀
Momentum Leaders
✗
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
✗
🛡
Low Volatility
✗
🏷
Sector Cheapest
✗
🧠
Capital Allocators
✗
⚡
Risk-Adj Momentum
RAM 4.60
V
Value Analysis
Cheapness relative to fundamentals
36.0%ile
P/S
9.6×
FCF Yield
-0.116
SH Yield
0.000
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
64.00000000
/100 — 1=cheapest
VC2 (Trending Value)
64.00000000
/100
VC3 (Buyback)
64.00000000
/100
Negative FCF yield (-11.6%) — the business is currently cash-consumptive.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
35.0%ile
ROE
1.072
ROA
-0.525
Net Margin
-0.948
Op Margin
-0.847
GPA
0.498
D/E
-3.04
Current
4.69
F-Score
1/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
0.529
Stability
0.281
lower=better
Accruals
0.128
lower=better
5yr Consist
Yes
ROE of 107% is exceptional. Conservative balance sheet with D/E of -3.04. Accruals ratio of 0.128 is elevated — earnings quality may be lower than headline numbers suggest. F-Score of 1/9 flags fundamental deterioration — multiple signals are weakening.
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
35.0%ile
6M Return
16.8%
12M Return
264.3%
12-1 Mom
298.9%
Risk-Adj
4.60
Vol 252d
65.0%
Vol 60d
137.8%
↑ Expanding
Max DD 12M
-40.4%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
12-1 momentum of 299% is very strong — a clear uptrend. Risk-adjusted momentum of 4.60 is excellent — strong returns relative to volatility. Near-term vol (138%) is expanding vs long-term (65%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.21
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare · 500 peers
Sector Value %ile
10.0%
Sector Quality %ile
10.2%
Sector Avg OS
63.3%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
IRWD Ironwood Pharmaceuticals Inc 99.0% 93.0% 86.0% 98.0%
FBIO Fortress Biotech Inc 98.0% 97.0% 93.0% 74.0%
RIGL Rigel Pharmaceuticals Inc 98.0% 94.0% 92.0% 76.0%
CGEN Compugen 97.0% 90.0% 95.0% 76.0%
PBYI Puma Biotechnology Inc 97.0% 80.0% 97.0% 92.0%
FBIOP Fortress Biotech Inc Pref Series A 97.0% 81.0% 95.0% 90.0%
WW WW International, Inc. Common Stock 97.0% 88.0% 80.0% 99.0%
MD Mednax Inc 96.0% 87.0% 80.0% 87.0%
Factor Interactions
Earnings Quality Concern
ROE looks strong (107%) but high accruals (0.128) suggests earnings are accrual-heavy, not cash-backed.
Volatility Expanding
60-day vol (138%) significantly exceeds 252-day (65%). Near-term risk is elevated.
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
F
16.0% avg (3 factors)
Quality
C
51.0% avg (8 factors)
Momentum
A
89.7% avg (4 factors)
Risk
F
8.3% avg (1 factors)
Elevated risk profile — position sizing should reflect the higher volatility.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Factor Persistence1 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.210—1—
Value %ile0.360—0—
Quality %ile0.350—0—
Momentum %ile0.350—0—
F-Score1.000—1—
Confidence0.758—1—
Volatility0.650—1—
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
Price / Sales
9.59
FCF Yield
-11.6%
Sales Yield (1/P·S)
0.0984
Shareholder Yield
Div + net buyback / mktcap
0.0%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
107.2%
Return on Assets
-52.5%
Net Margin
-94.8%
Operating Margin
-84.7%
Gross Profit / Assets
Novy-Marx GPA
49.8%
Debt / Equity
-3.04
Current Ratio
4.69
Accruals Ratio
(NI-OCF)/Assets — lower=better
0.128
MomentumPrice trend strength over different horizons
6M Return
16.8%
12M Return
264.3%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
298.9%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
4.60
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
52.9%
Earnings Stability (CV)
Lower = more stable
0.281
5yr Consistent
EPS up every year for 5 years
Yes
Piotroski F-Score
1
Dividend Yield
0.0%
Buyback Yield
0.0%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
64
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
64
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
64
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity